| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S12026-007-8009-6 |
| P698 | PubMed publication ID | 17960498 |
| P2093 | author name string | Takahiro Ito | |
| Cornelia Cudrici | |||
| Horea Rus | |||
| Sangjin Oh | |||
| P2860 | cites work | Pathogenetic role of autoantibodies in neurological diseases | Q28138484 |
| Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event | Q28186287 | ||
| Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion | Q28253124 | ||
| Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination | Q29614990 | ||
| Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia | Q30312115 | ||
| Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis | Q30444852 | ||
| Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes | Q33336433 | ||
| Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura | Q33365619 | ||
| Treatment with rituximab in benign and malignant hematologic disorders in children | Q33374660 | ||
| A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica | Q33727402 | ||
| Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination | Q33916977 | ||
| B cells and antibodies in CNS demyelinating disease | Q34100103 | ||
| B cells regulate autoimmunity by provision of IL-10. | Q34150590 | ||
| Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. | Q34253953 | ||
| Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice | Q34411828 | ||
| Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients | Q35585366 | ||
| Rituximab: expanding role in therapy for lymphomas and autoimmune diseases | Q35640302 | ||
| B-cell differentiation in the CNS of patients with multiple sclerosis | Q36281252 | ||
| Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis | Q36351504 | ||
| Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis | Q36375265 | ||
| C5b-9 complement complex in autoimmune demyelination: dual role in neuroinflammation and neuroprotection | Q36558440 | ||
| A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis | Q36891696 | ||
| Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. | Q37285430 | ||
| Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy | Q37368148 | ||
| Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes | Q37371756 | ||
| Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis | Q37381504 | ||
| The significance of perivascular infiltrations in multiple sclerosis | Q39372080 | ||
| Immunoglobulin-containing cells in multiple-sclerosis plaques | Q39450637 | ||
| Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis | Q40141450 | ||
| The current status of multiple sclerosis intra-blood-brain-barrier IgG synthesis | Q40202336 | ||
| Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody | Q40594100 | ||
| AN ELECTROPHORETIC STUDY OF THE PROTEIN COMPONENTS IN CEREBROSPINAL FLUID AND THEIR RELATIONSHIP TO THE SERUM PROTEINS. | Q40973713 | ||
| Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord | Q41466361 | ||
| CSF antibody to myelin basic protein. Measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis | Q41537620 | ||
| Immunocytochemical localization of the terminal complement complex in multiple sclerosis. | Q41895702 | ||
| A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis | Q43492392 | ||
| Induction of anti-myelin antibodies in EAE and their possible role in demyelination. | Q46172827 | ||
| Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis | Q46266579 | ||
| Identification of autoantibodies associated with myelin damage in multiple sclerosis | Q46424597 | ||
| An open label study of the effects of rituximab in neuromyelitis optica | Q46482210 | ||
| Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
| Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects | Q47376541 | ||
| Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis | Q47725513 | ||
| Complement activation determines the therapeutic activity of rituximab in vivo. | Q47745204 | ||
| Intrathecal activation of the complement system and disability in multiple sclerosis | Q47995950 | ||
| Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis | Q48219268 | ||
| Endogenous myelin basic protein is presented in the periphery by both dendritic cells and resting B cells with different functional consequences. | Q48455262 | ||
| Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination | Q48489118 | ||
| Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis | Q48913563 | ||
| Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis | Q48949365 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Multiple sclerosis: brain immunoglobulin-G and albumin. | Q51213357 | ||
| Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins. | Q53775519 | ||
| Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange | Q61709608 | ||
| Patterns of oligodendroglia pathology in multiple sclerosis | Q61709808 | ||
| Terminal complement complexes (SC5b-9) in cerebrospinal fluid in autoimmune nervous system diseases | Q67997374 | ||
| Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown | Q70180407 | ||
| Plasma exchange in acute multiple sclerosis. Design of a cooperative study | Q70288413 | ||
| Plasmapheresis in multiple sclerosis: preliminary findings | Q70532913 | ||
| Plasmapheresis in multiple sclerosis: preliminary study | Q70653489 | ||
| Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone | Q70677798 | ||
| CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone | Q73083398 | ||
| B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide | Q73170385 | ||
| Recovery from EAE is associated with decreased survival of encephalitogenic T cells in the CNS of B7-1/B7-2-deficient mice | Q73716882 | ||
| B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis | Q79880391 | ||
| Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment | Q80201632 | ||
| Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis | Q81208768 | ||
| Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis | Q81335025 | ||
| Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis | Q81401055 | ||
| The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions | Q81485093 | ||
| P433 | issue | 3 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 224-234 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Immunologic Research | Q15754981 |
| P1476 | title | B-cells and humoral immunity in multiple sclerosis. Implications for therapy | |
| P478 | volume | 40 |
| Q37336914 | Complement in multiple sclerosis: its role in disease and potential as a biomarker. |
| Q37541906 | Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis |
| Q48186044 | Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis |
| Q27659556 | Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus |
| Q35577914 | Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis |
Search more.